Suggested remit: To appraise the clinical and cost effectiveness of finerenone within its marketing authorisation for treating chronic kidney disease in people with type 2 diabetes.
 
Status In progress
Decision Selected
Process STA 2018
ID number 3773

Provisional Schedule

Expected publication 14 September 2022

Project Team

Project lead Daniel Davies

Email enquiries

External Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Stakeholders

Companies sponsors Bayer (finerenone)
Others Department of Health and Social Care
  NHS Eastern Cheshire CCG
  NHS England
  NHS South West Lincolnshire CCG
  Welsh Government
Patient carer groups Kidney Care UK
  UK Kidney Association
Professional groups Association of British Clinical Diabetologists
  Primary Care Diabetes Society
  Royal College of Physicians
  UK Clinical Pharmacy Association
Associated public health groups None
Comparator companies AstraZeneca (dapagliflozin)
  Boehringer Ingelheim (empagliflozin)
  Merck Sharp & Dohme (ertugliflozin)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Welsh Kidney Patients Association
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
12 May 2022 - 06 June 2022 Draft guidance
14 April 2022 Committee meeting: 1
28 June 2021 Invitation to participate
25 June 2021 In progress. In progress
03 March 2021 - 31 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual